RUBY Trial Design, Efficacy, and Real-World Evidence for Dostarlimab

Dr. Konecny reviews the design and key efficacy findings of the RUBY trial, the first large randomized study to evaluate dostarlimab in combination with carboplatin and paclitaxel as frontline therapy for advanced or recurrent endometrial cancer. He describes the eligibility criteria, dosing schedule, and the striking outcomes observed in both mismatch repair–deficient and mismatch repair–proficient patient populations, including a approximately 70% risk reduction in progression-free survival in the deficient group and a statistically significant 25% risk reduction in the proficient group. Dr. Wenham and Dr. Konecny also contrast the RUBY and NRG-GY018 trial designs. Dr. Redfern then addresses how these results translate to real-world populations, citing evidence presented at ASCO 2025 demonstrating comparable outcomes, and shares her own clinical experience incorporating dostarlimab into routine practice.